A5088021109- SARS-CoV-2 and COVID-19 Research
- COVID-19 diagnosis using AI
- Cancer-related Molecular Pathways
- HER2/EGFR in Cancer Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- COVID-19 epidemiological studies
- vaccines and immunoinformatics approaches
- Animal Virus Infections Studies
- Advanced Breast Cancer Therapies
Veterinary and Food Board
2021-2024
State Healthcare Institution "Regional Clinical Oncological Dispensary"
2024
We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant reported by seven European countries. COVID-19 with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0–2.9; B.1.351: 3.6, CI: 2.1–6.2; P.1: 2.6, 1.4–4.8) B.1.1.7/SGTF also intensive care admission 2.3, 1.4–3.5; 2.2, 1.7–2.8).
Background The COVID-19 pandemic was characterised by rapid waves of disease, carried the emergence new and more infectious SARS-CoV-2 virus variants. How unfolded in various locations during its first two years has yet to be sufficiently covered. To this end, here we are looking at circulating variants, their diversity, hospitalisation rates Estonia period from March 2000 2022. Methods We sequenced a total 27,550 samples between 2020 High-quality sequences were genotyped assigned Nextstrain...
Purpose We aimed to describe SARS-CoV-2 lineages and diversity in children adults Estonia similarity travel-related cases neighbouring countries. Methods sequences 2021–2022 from a nationwide study were included. The proportion of predominant Estonian regions among was described by multinomial logistic regression. Simpson’s indices compared using linear Dynamics Bray-Curtis dissimilarity applying fuzzy clustering non-metrical dimensional scaling results. Results A total 2,630 (<15 years)...
Background. The use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in combination with endocrine therapy is a key initial treatment for advanced luminal HER2-negative (HR+/HER2-) breast cancer. approval studies MONALEESA-2 7 demonstrated the efficacy safety ribociclib aromatase as first-line post- premenopausal patients. In Phase lllb CompLEEment-1 study, same regimen was evaluated an extended patient population terms both efficacy. article presents analysis data from subgroup...